Overview

* Collegium Q2 product net revenue rises 29% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 beats consensus, reflecting operational efficiency

* Co announces $150 mln share repurchase program, indicating confidence in future growth

Outlook

* Collegium raises full-year 2025 revenue guidance to $745-$760 mln

* Company expects full-year 2025 adjusted EBITDA of $440-$455 mln

Result Drivers

* JORNAY PM GROWTH - Jornay PM prescriptions grew 23% year-over-year, contributing to record net revenue of $32.6 mln

* PAIN PORTFOLIO - Pain portfolio revenue rose 7% year-over-year, with all core products showing growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $188 mln $180.90

Revenue mln (4

Analysts

)

Q2 Beat $1.68 $1.62 (3

Adjusted Analysts

EPS )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Collegium Pharmaceutical Inc ( COLL ) is $46.00, about 35.3% above its August 6 closing price of $29.75

* The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)